Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Taps Scientific Heavyweight John Reed To Head Early Pharma R&D

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche has enlisted John Reed - head of the La Jolla-based Sanford-Burnham Medical Research Institute - to lead the Swiss group’s non-Genentech pharmaceutical R&D efforts.

You may also be interested in...

Sanford-Burnham Hopes $275 Million Gift Will Translate To Returns

As NIH funding becomes increasingly scarce, the La Jolla, Calif., research institute will use an anonymously donated gift to emphasize translational projects and take internal risk. Will it deliver returns that sustain the organization?

Research And Early Development At Roche, A Work In Progress: An Interview With Mike Burgess

The acting head of Roche pharma research and early development stepped into the job amid major personnel changes in the pharma organization and the consolidation and streamlining of pRED. He spoke with the “The Pink Sheet” about his group’s priorities and the inevitable short-term hit to research productivity.

AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division

AstraZeneca has appointed an experienced biotech and pharmaceuticals executive, Pascal Soriot, to its vacant CEO position, while Roche switches Daniel O'Day from its diagnostics to its pharmaceuticals division.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts